Ottawa, ON / BusinessWire/ October 8, 2019/ – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, is pleased to announce that it has received its first order for OxC-beta™ Livestock in Taiwan, specifically for the use in poultry and sow feeds.
The 200 kilogram order comes from More Standing Enterprise Co., Ltd., a leading manufacturer based in Taiwan of animal nutrition products for improving animal production efficiency in the premix industry in Taiwan and Southeast Asia. This introductory order comes after several successful testing programs.
“Today’s new order is further evidence that feed producers around the world are recognizing the substantial benefit that OxC-beta™ Livestock provides in improving the health and performance of multiple food producing animal species and allowing the phasing out of non-medicinal use of antibiotics. While reducing antibiotic use is a major benefit, customers are also recognizing our product’s positive impacts on aspects of animal performance that go beyond the antibiotic alternative role, improving the reproductive performance and milk quality of sows being a prime example,” said Kym Anthony, Chief Executive Officer, Avivagen Inc. “With commercial use for sows now in place in multiple markets, we anticipate a considerable increase in short and long-term interest from and use in many more markets around the world.”
With a total of nearly 3.25 million tonnes of sow feed and nearly 3.5 million tonnes of poultry feed produced annually, Taiwan represents a new growth market for Avivagen’s OxC-beta™ Livestock product and expands its use across Asia Pacific. Beyond Taiwan, use of OxC-beta™ Livestock has been ramping up steadily in the Philippines and Thailand, and Avivagen believes that the scale-up of OxC-beta™ Livestock use in Taiwan will mirror that of other markets in the region.
Use in sow feeds is of particular significance as it provides further commercial validation of research findings showing that OxC-beta™ Livestock positively impacts sow health, milk quality and the health of nursing piglets. Commercial validation in Taiwan follows the same validation in Thailand, and is expected to positively influence adoption for use in sows in other countries in both Asia Pacific and around the globe.
OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the U.S. (GRAS), the Philippines, Taiwan, Thailand, New Zealand, Mexico and Australia. Avivagen intends to accelerate market access and the commercial uptake of its OxC-beta™ Livestock product, a product that has the potential to eliminate the use of antibiotics as growth promoters in livestock feed, which is a problem that needs an urgent solution and which represents a multi-billion dollar market opportunity.
Avivagen is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours, and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the U.S. (GRAS), the Philippines, Taiwan, Thailand, New Zealand, Mexico and Australia.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements set out in this news release relating to the anticipation of an increase in short and long-term interest from and use in more markets around the world, the expectation that the scale-up of OxC-beta™ Livestock use in Taiwan will mirror that of other markets in the region, the expectation that sales in Taiwan will positively influence adoption for use in sows in other countries in both Asia Pacific and around the globe, the possibility for deployment or launch of OxC-beta™ Livestock in new jurisdictions around the world or for it to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded, Avivagen’s intention to accelerate market access and the commercial uptake of its OxC-beta™ Livestock product and the size of market opportunities are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, sales in Taiwan may not result in an increase in interest for Avviagen’s products and may not influence buying behaviors in other jurisdictions, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds, new market access may not occur in the timeline or manner expected by Avivagen and the market opportunities may not be as large as Avivagen anticipates due to many factors, many of which are outside of Avivagen’s control. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164